A First-in-Human Study of HH160 in Patients With Advanced Solid Tumors

Summary

This study is evaluating the safety, side effects, how the body processes HH160, and its early anticancer activity when given alone or with other cancer treatments in participants with advanced solid tumors. The study will also identify the recommended dose for future studies. The trial includes two phases and is expected to last about 4 years, with treatment and follow-up lasting approximately 6-12 months each.

Timeline

Start

2026-06

Primary completion

2028-08

Completion

2028-08

Drugs

Indications